Periscope Capital’s Jasper Therapeutics JSPR Stock Holding History

Periscope Capital’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,040	Closed	-$998K	–	879
2021 Q2	$998K	Hold	10,040	–	–	0.03%	511
2021 Q1	$996K	Hold	10,040	–	–	0.04%	411
2020 Q4	$1M	Hold	10,040	–	–	0.05%	285
2020 Q3	$996K	Hold	10,040	–	–	0.07%	207
2020 Q2	$1.02M	Buy	+10,040	New	+$981K	0.09%	152

Other funds holding JSPR

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPARFS

Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Periscope Capital's JSPR Position: Q3 2021 in Review

Periscope Capital sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 10,040 shares — an estimated $998K sold.

Periscope Capital first reported a position in JSPR in Q2 2020 and held it in 5 quarters. The position peaked at $1.02M in Q2 2020. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

Periscope Capital reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
Periscope Capital sold 10,040 Jasper Therapeutics shares in Q3 2021, an estimated $998K.
Periscope Capital first reported a position in Jasper Therapeutics in Q2 2020 and held it in 5 quarters.
Periscope Capital's Jasper Therapeutics position peaked at $1.02M in Q2 2020.
10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on Periscope Capital's 13F filing for Q3 2021, filed 12 Nov 2021.